HIV pharmacology: barriers to the eradication of HIV from the CNS

HIV Clin Trials. May-Jun 2006;7(3):142-53. doi: 10.1310/AW2H-TP5C-NP43-K6BY.

Abstract

Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in up to one fifth of untreated patients. This review summarizes current theory regarding HIV-1 infection within the CNS, describes physiologic and pharmacologic factors limiting CNS penetration of antiretroviral drugs used to treat HIV-1 infection, and reviews current treatment of CNS HIV-1 infection and HIV encephalopathy.

Publication types

  • Review

MeSH terms

  • AIDS Dementia Complex / drug therapy
  • Animals
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / virology
  • CD4-Positive T-Lymphocytes / virology
  • Central Nervous System / blood supply
  • Central Nervous System / virology
  • Central Nervous System Viral Diseases / drug therapy*
  • Central Nervous System Viral Diseases / virology*
  • HIV Infections / drug therapy*
  • HIV-1* / physiology
  • Humans
  • Macrophages / virology
  • Monocytes / virology
  • Virus Latency

Substances

  • Anti-HIV Agents